New Delhi, February 25 Drug firm Lupin announced on Wednesday that it has received approval from the US health regulator to market a generic medication to treat seizures.
The Mumbai-based firm has received approval from the USFDA for its abbreviated new drug application (ANDA) for Brivaracetam Oral Solution (10 mg/mL), it said in a statement.
Brivaracetam is bioequivalent to UCB, Inc's Briviact Oral Solution (10 mg/mL) and is indicated for the treatment of partial-onset seizures in patients.
Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the US, it stated.
According to industry estimates, Brivaracetam Oral Solution had an estimated annual sale of USD 135 million in the US.
Lupin shares were trading up 0.98 per cent at Rs 2,273.10 apiece on the BSE.
